Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis

Prophylaxis against febrile neutropenia with pegfilgrastim in Italy: a budget impact analysis

Introduction: prophylaxis with granulocyte colony-stimulating factors (G-CSF) is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy. Objective: to evaluate the budgetary impact for the Italian...

Full description

Bibliographic Details
Main Authors:	Giovanni Rosti, Maria Lebboroni, Ario Cerchiari, Pablo Katz
Format:	Article
Language:	English
Published:	SEEd Medical Publishers 2011-09-01
Series:	Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:	pegfilgrastim neutropenia febbrile budget impact
Online Access:	https://journals.seedmedicalpublishers.com/index.php/FE/article/view/126

Similar Items

On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: Current Status
by: Ivo Abraham, et al.
Published: (2024-01-01)

A Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy
by: Roberto Ravasio, et al.
Published: (2020-03-01)

Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study
by: Youngwoo Jeon, et al.
Published: (2023-03-01)

Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
by: Girma Tekle Gebremariam, et al.
Published: (2022-12-01)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
by: Esse I. H. Akpo, et al.
Published: (2017-09-01)

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study
by: Patrick Wayne Cobb, et al.
Published: (2020-09-01)

Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
by: Patrizia Berto, et al.
Published: (2022-02-01)

Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage
by: Jeffrey Crawford, et al.
Published: (2021-01-01)

Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051
by: Keita Miura, et al.
Published: (2024-02-01)

Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety
by: Reshma Mahtani, et al.
Published: (2021-05-01)

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study
by: Derek Weycker, et al.
Published: (2019-08-01)

Safety and tolerability of Peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India
by: Vineet Talwar, et al.
Published: (2017-01-01)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
by: Kosuke Hamai, et al.
Published: (2023-04-01)

Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study
by: Wen Zhao, et al.
Published: (2024-08-01)

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy
by: Kalpna Desai, et al.
Published: (2018-09-01)

New developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastim
by: Ghidini M, et al.
Published: (2016-06-01)

Efficacy and safety of pegfilgrastim biosimilar MD‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III
by: Toshimi Takano, et al.
Published: (2023-10-01)

Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
by: Shinya Tsuboi, et al.
Published: (2023-01-01)

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
by: Zsuzsanna Kahan, et al.
Published: (2019-02-01)

Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer
by: Motoki Sekikawa, et al.
Published: (2023-12-01)

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
by: Guariglia R, et al.
Published: (2016-01-01)

Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis
by: Xia Zhu, et al.
Published: (2023-12-01)

Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01)

Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis
by: Shruti Rastogi, et al.
Published: (2021-10-01)

Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia
by: María Alejandra Larrarte-González, et al.
Published: (2023-05-01)

Primary Prophylaxis Lapelga<sup>®</sup> in Early Breast Cancer: A Real-World Experience
by: Fahad Khan, et al.
Published: (2023-03-01)

NEUTROPENIA FEBRIL EN PEDIATRIA Febrile Neutropenia in Pedriatrics
by: Pio Lopez, et al.
Published: (2008-03-01)

Immunogenicity Assessment of Pegfilgrastim in Patients with Breast Cancer
by: Yu. V. Medvedev, et al.
Published: (2020-05-01)

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations
by: V. V. Ptushkin, et al.
Published: (2015-06-01)

Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations
by: V. V. Ptushkin, et al.
Published: (2015-06-01)

How I treat febrile neutropenia
by: Marcio Nucci
Published: (2021-02-01)

Pegfilgrastim-related thoracic aortitis: A case report and literature review
by: Chikako Sekine, et al.
Published: (2023-09-01)

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial
by: Chris Wynne, et al.
Published: (2020-04-01)

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
by: Ga-Young Song, et al.
Published: (2023-10-01)

Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy
by: Maria Bachlitzanaki, et al.
Published: (2023-10-01)

Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia
by: Otremba B, et al.
Published: (2018-10-01)

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey
by: Innocenti R, et al.
Published: (2018-12-01)

Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial
by: Safa Najafi, et al.
Published: (2021-04-01)

Study of PEG-Filstim sub-acute toxicity
by: V. L. Karbovskyi, et al.
Published: (2018-08-01)

Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines
by: Doaa Naeem, et al.
Published: (2018-08-01)